PBYI News and Press, Puma Biotechnology Inc From 02/13/24

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the initiation of its ALISertib in CAncer (ALISCA-Lung1) Phase II trial (PUMA-ALI-4201; NCT06095505) of alisertib monotherapy for the treatment of patients with extensive stage small cell lung cancer. The ALISCA-Lung1...

2024-01-31 12:58:26 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Penny stocks are generally defined as stocks that trade for less than $5 per share. Low-priced stocks appeal to investors who can wait for these stock prices to appreciate. I say patience b...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company (the “Company”), announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company on January 18, 2024 at the virtual B. Riley Securities 4 ...

2023-12-14 01:41:25 ET Summary Puma Biotechnology is a commercial-stage biotech with a struggling approved drug, neratinib, but potential for gains. The company is focused on refining current indications for neratinib and investigating dose optimization. Puma Biotechnology's g...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company (the Company), announced the design of the Phase II trial of alisertib for the treatment of patients with HER2-negative, hormone receptor-positive metastatic breast cancer (PUMA-ALI-1201). Based on the Company’s interacti...

2023-11-13 08:32:18 ET Tivic Health Systems Inc ( TIVC ) +108% . Collective Audience Inc ( CAUD ) +35% . FREYR Battery ( FREY ) +17% Publishes Shareholder Letter. RLX Technology Inc ADR ( RLX ) +12% Q3 earnings call release Babcock &...

2023-11-02 22:21:06 ET Puma Biotechnology, Inc. (PBYI) Q3 2023 Earnings Conference Call November 02, 2023, 04:30 PM ET Company Participants Mariann Ohanesian - Senior Director, IR Alan Auerbach - Chairman, President and CEO Maximo Nougues - CFO Jeff Ludwig - ...

2023-11-02 16:58:49 ET Puma Biotechnology press release ( NASDAQ: PBYI ): Q3 Non-GAAP EPS of $0.17 beats by $0.03 . Revenue of $56.1M (-1.8% Y/Y) misses by $1.85M . Fourth Quarter and Full Year 2023 Financial Outlook For further details see: P...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2023. Unless otherwise stated, all comparisons are for the third quarter of 2023 compared to the third quarter of 2022. Product revenue, net consists ent...

Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...